Abstract
A key step in the processing of the integral membrane protein APP, or Amyloid Precursor Protein is through the proteolytic cleavage by the enzyme β-Secretase (BACE). The proteolysis of APP by BACE, followed by subsequent C-terminal cleavage(s) by γ-secretase, results in the formation of the amyloidβ(Aβ ) peptide. The principal component of the neuritic plaque found in the brains of Alzheimers Disease (AD) patients is Aβ which is a neurotoxic and highly aggregatory peptide segment of APP. The amyloid hypothesis holds that the neuronal dysfunction and clinical manifestation of AD is a consequence of the long term deposition and accumulation of 40-42 amino-acid long A β peptides, and that this process leads to the onset and progression of AD. Due to the apparent causal relationship between Aβ and AD, the so-called "secretases" that produce Aβ have been targeted for development of inhibitors that might serve as therapeutic agents for treatment of this dreaded, and ever more prevalent disease. Herein will be discussed our current understanding of BACE, its role in the formation of neuritic plaques and the known inhibitors of the enzyme.
Keywords: amyloidogenic pathway, Alzheimer, ’, s disease, Hydroxyethylene inhibitors, APP processing, hydroxymethylcarbonyl (HMC)
Current Topics in Medicinal Chemistry
Title: Human β-secretase (BACE) and BACE Inhibitors: Progress Report
Volume: 6 Issue: 6
Author(s): Varghese John
Affiliation:
Keywords: amyloidogenic pathway, Alzheimer, ’, s disease, Hydroxyethylene inhibitors, APP processing, hydroxymethylcarbonyl (HMC)
Abstract: A key step in the processing of the integral membrane protein APP, or Amyloid Precursor Protein is through the proteolytic cleavage by the enzyme β-Secretase (BACE). The proteolysis of APP by BACE, followed by subsequent C-terminal cleavage(s) by γ-secretase, results in the formation of the amyloidβ(Aβ ) peptide. The principal component of the neuritic plaque found in the brains of Alzheimers Disease (AD) patients is Aβ which is a neurotoxic and highly aggregatory peptide segment of APP. The amyloid hypothesis holds that the neuronal dysfunction and clinical manifestation of AD is a consequence of the long term deposition and accumulation of 40-42 amino-acid long A β peptides, and that this process leads to the onset and progression of AD. Due to the apparent causal relationship between Aβ and AD, the so-called "secretases" that produce Aβ have been targeted for development of inhibitors that might serve as therapeutic agents for treatment of this dreaded, and ever more prevalent disease. Herein will be discussed our current understanding of BACE, its role in the formation of neuritic plaques and the known inhibitors of the enzyme.
Export Options
About this article
Cite this article as:
John Varghese, Human β-secretase (BACE) and BACE Inhibitors: Progress Report, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743084
DOI https://dx.doi.org/10.2174/156802606776743084 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unique Insights into the Actions of CNS Agents: Lessons from Studies of Chlorpyrifos and Other Common Pesticides
Central Nervous System Agents in Medicinal Chemistry The S100A8 and S100A9 Proteins are Attractive Targets to Modulate Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]
Current Vascular Pharmacology COMMENTARY: Transcranial Magnetic Stimulation in Multiple Sclerosis: A Method to Improve Movement
CNS & Neurological Disorders - Drug Targets Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD
Current Respiratory Medicine Reviews Fundamental, Electron Transfer Mechanism by Pyrylium-Type Ions for the Anticancer Drugs 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) and Flavone-8-Acetic Acid (FAA)
Current Medicinal Chemistry - Anti-Cancer Agents Functional Role of β-Turn in Polypeptide Structure and its use as Template to Design Therapeutic Agents
Central Nervous System Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design Overcoming Treatment Barriers in Adolescent Psychiatry
Adolescent Psychiatry Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer’s Disease and Correlation with Cerebral Hypoperfusion Pattern
Current Alzheimer Research Serotonin Type-4 (5-HT4) Receptors as Therapeutic Targets: Past and Future Roles of 5-HT4 Receptor Agonists
Current Medicinal Chemistry - Central Nervous System Agents Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry State of the Evidence: Intimate Partner Violence and HIV/STI Risk Among Adolescents
Current HIV Research Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Current Neurovascular Research MicroRNA-130b Promotes Wear Particle-Induced Osteolysis via Downregulating Frizzled-Related Protein (FRZB)
Current Neurovascular Research